← All trials
NCT05662020
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2022
- Primary completion
- Nov 7, 2022
- Completion date
- Mar 23, 2028
- First posted
- Dec 22, 2022
- Last posted
- Dec 26, 2022
- Enrollment
- 2750
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Beijing Health Guard Biotechnology, IncLead sponsor
- Beijing Health Guard Biotechnology, IncStudy chair
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Beijing Health Guard Biotechnology, IncOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.